Related Experiment Video
Updated: Jul 20, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated
1Department of Internal Medicine, Branch Hospital, Nagoya University School of Medicine, Japan.
Abstract:
beta 2-Microglobulin (beta 2M) is a major constituent of amyloid fibrils in hemodialysis-associated amyloidosis, a complication of long-term hemodialysis patients. Amyloid fibril proteins were isolated from connective tissues forming carpal tunnels in hemodialysis patients with carpal tunnel syndrome. Two-dimensional polyacrylamide gel electrophoresis and Western blotting demonstrated that most of the beta 2M forming amyloid fibrils exhibited a more acidic pI value than normal beta 2M. This acidic beta 2M was also found in a small fraction of beta 2M in sera and urine from these patients, whereas heterogeneity was not observed in healthy individuals. We purified acidic and normal beta 2M from the urine of long-term hemodialysis patients and compared their physicochemical and immunochemical properties. Acidic beta 2M, but not normal beta 2M, was brown in color and fluoresced, both of which are characteristics of advanced glycation end products (AGEs) of the Maillard reaction. Immunochemical studies showed that acidic beta 2M reacted with anti-AGE antibody and also with an antibody against an Amadori product, an early product of the Maillard reaction, but normal beta 2M did not react with either antibody. Incubating normal beta 2M with glucose in vitro resulted in a shift to a more acidic pI, generation of fluorescence, and immunoreactivity to the anti-AGE antibody. The beta 2M forming amyloid fibrils also reacted with anti-AGE antibody. These data provided evidence that AGE-modified beta 2M is a dominant constituent of the amyloid deposits in hemodialysis-associated amyloidosis.
Insights
Advanced glycation end product (AGE)-modified beta 2-microglobulin (beta 2M) is a primary component of amyloid deposits in hemodialysis-associated amyloidosis. This modification explains the altered properties of beta 2M found in patients undergoing long-term hemodialysis.
Area of Science:
- Biochemistry
- Nephrology
- Pathology
Background:
- Hemodialysis-associated amyloidosis is a complication in patients with long-term kidney failure.
- Beta 2-microglobulin (beta 2M) is a major protein component of amyloid fibrils in this condition.
- The exact nature of beta 2M modification leading to amyloid formation is not fully understood.
Purpose of the Study:
- To investigate the physicochemical and immunochemical properties of beta 2M in hemodialysis-associated amyloidosis.
- To determine if beta 2M in amyloid deposits is modified.
- To elucidate the role of glycation in the pathogenesis of beta 2M amyloidosis.
Main Methods:
- Isolation and purification of beta 2M from carpal tunnel connective tissues and urine of hemodialysis patients.
- Two-dimensional polyacrylamide gel electrophoresis and Western blotting to analyze beta 2M properties.
- Physicochemical analysis including pI determination, color, and fluorescence measurement.
- Immunochemical assays using anti-AGE and anti-Amadori antibodies.
- In vitro glycation of normal beta 2M with glucose.
Main Results:
- Amyloid-associated beta 2M exhibited a more acidic isoelectric point (pI) compared to normal beta 2M.
- Acidic beta 2M showed brown coloration and fluorescence, characteristic of advanced glycation end products (AGEs).
- Acidic beta 2M reacted with antibodies against AGEs and Amadori products, while normal beta 2M did not.
- In vitro glycation of beta 2M induced similar changes in pI, fluorescence, and immunoreactivity.
- Beta 2M from amyloid fibrils also reacted with anti-AGE antibodies.
Conclusions:
- AGE-modified beta 2M is a dominant constituent of amyloid deposits in hemodialysis-associated amyloidosis.
- Glycation of beta 2M, a process related to the Maillard reaction, leads to its altered properties and amyloid formation.
- These findings highlight the role of protein glycation in the development of dialysis-related amyloid complications.
More Related Videos
10:51Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting
Published on: April 10, 2014
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Proteoglycans
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...
Nephrotic Syndrome I : Introduction
Diabetic Nephropathy